Ambulatory Assist Lung for Children

急性和慢性肺部疾病仍然是最威胁生命的死亡和住院原因 儿科人口。观察到囊性纤维化(CF)、肺动脉高压和肺纤维化 是导致儿科患者肺衰竭的最常见原因。机械通风(MV)和 体外膜氧合(ECMO)已被用于连接患病儿童与移植的桥梁。这些 由于手术对移动性的限制，手术可能会导致移植后不良的结果。这个项目 将为儿科患者开发一种紧凑型呼吸辅助装置，匹兹堡儿科非卧床肺 (P-PAL)取代ECMO，成为急慢性肺衰竭儿童移植或康复的桥梁。这个 P-PAL是一款可穿戴的完全集成的血泵和气体交换模块，将为 分别在右心房和肺动脉植入流入管和流出管/移植物。 P-PAL将被设计用于更长期的呼吸支持(在子弹更换前1-3个月)，在70- 90%的正常代谢氧合需求，同时泵血速度从1升/分钟到2.5升/分钟。具体的 项目的目标是1)修改P-PAL的设计和运行参数，以满足以下要求 抽血、气体交换、预充量和形状系数，2)沿着设计建立P-PAL原型 泵送性能、气体交换和气体交换台架表征研究的发展途径 溶血；3)通过开发新型聚合物两性离子来改善P-PAL的血液相容性 我们已经开始为我们的成人可穿戴辅助肺开发涂层，以及4)执行急性 在健康羔羊身上进行的慢性研究，以证明该疫苗的体内表现和血液相容性 并研究其与心肺系统的相互作用。

Acute and chronic lung diseases remain the most life threatening causes of death and hospitalization in the pediatric population. Cystic fibrosis (CF), pulmonary hypertension and pulmonary fibrosis have been observed to be the most frequent causes of lung failure in pediatric patients. Mechanical ventilation (MV) and extracorporeal membrane oxygenation (ECMO) have been used to bridge sick kids to transplant. These procedures can lead to poor post-transplant outcomes by their very restrictive nature on mobility. This project will develop a compact respiratory assist device for pediatric patients, the Pittsburgh Pediatric Ambulatory Lung (P-PAL) to replace ECMO as a bridge to transplant or recovery in kids with acute and chronic lung failure. The P-PAL is a wearable and fully integrated blood pump and gas exchange module that will be designed for implantation of inflow cannula and outflow cannula/grafts in the right atrium and pulmonary artery, respectively. The P-PAL will be designed for longer-term respiratory support (1-3 months before cartridge change-out) at 70- 90% of normal metabolic oxygenation requirements, while pumping blood from 1 to 2.5 Liters/min. The specific aims of project are 1) To modify the design and operational parameters of the P-PAL to meet requirements for blood pumping, gas exchange, priming volume, and form factor, 2) To build P-PAL prototypes along the design development pathway for bench characterization studies of pumping performance, gas exchange, and hemolysis, 3) To improve the hemocompatibility of the P-PAL by exploiting novel polymeric zwitterionic coatings that we have already begun to develop for our adult wearable assist lung, and 4) To perform acute and chronic studies in healthy lambs to demonstrate the in-vivo performance and hemocompatibility of the PAAL device and to study its interaction with the cardiopulmonary system.